[go: up one dir, main page]

PE20121475A1 - Nuevos derivados de azabiciclo[3.1.0]hex-2-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados de azabiciclo[3.1.0]hex-2-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Info

Publication number
PE20121475A1
PE20121475A1 PE2012000722A PE2012000722A PE20121475A1 PE 20121475 A1 PE20121475 A1 PE 20121475A1 PE 2012000722 A PE2012000722 A PE 2012000722A PE 2012000722 A PE2012000722 A PE 2012000722A PE 20121475 A1 PE20121475 A1 PE 20121475A1
Authority
PE
Peru
Prior art keywords
hex
ilo
preparation procedure
azabiciclo
pharmaceutical compositions
Prior art date
Application number
PE2012000722A
Other languages
English (en)
Inventor
Patrick Casara
Alain Dhainaut
Pierre Lestage
Anne-Marie Chollet
Jean-Michel Henlin
Fany Panayi
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42711699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121475(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20121475A1 publication Critical patent/PE20121475A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DERIVADO DE AZABICICLO[3.1.0]HEX-2-ILO DE FORMULA (I) DONDE: ALK ES UNA CADENA DE ALQUILENO TALES COMO ETILENO O PROPILENO; W ES UN GRUPO TAL COMO -CO-NH2, -CO-NH-CH3, -CO-N(CH3)2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-{3-(CIS-2-AZABICICLO[3.1.0]HEX-2-IL(PROPOXI}-N,N-DIMETILBENZAMIDA; N-(4-{3-(CIS-2-AZABICICLO[3.1.0]HEX-2-IL)PROPOXI}FENIL)ACETAMIDA; N-(4-{3-(CIS-2-AZABICICLO[3.1.0]HEX-2-IL)PROPOXI}FENIL)-2-METOXIACETAMIDA; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS TALES COMO ENFERMEDAD DE ALZHEIMER, PARKINSON, DEMENCIA VASCULAR, ESCLEROSIS EN PLACAS
PE2012000722A 2009-12-09 2010-12-08 Nuevos derivados de azabiciclo[3.1.0]hex-2-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen PE20121475A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0905953A FR2953521B1 (fr) 2009-12-09 2009-12-09 Nouveaux derives azabicyclo[3.1.0]hex-2-yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PE20121475A1 true PE20121475A1 (es) 2012-10-20

Family

ID=42711699

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000722A PE20121475A1 (es) 2009-12-09 2010-12-08 Nuevos derivados de azabiciclo[3.1.0]hex-2-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Country Status (32)

Country Link
US (1) US20120283245A1 (es)
EP (1) EP2509947A1 (es)
JP (1) JP2013513589A (es)
KR (1) KR20120102763A (es)
CN (1) CN102652127A (es)
AP (1) AP2012006352A0 (es)
AR (1) AR079265A1 (es)
AU (1) AU2010329762B2 (es)
BR (1) BR112012013666A2 (es)
CA (1) CA2782469C (es)
CL (1) CL2012001479A1 (es)
CO (1) CO6541535A2 (es)
CR (1) CR20120286A (es)
CU (1) CU20120091A7 (es)
EA (1) EA201200849A1 (es)
EC (1) ECSP12011950A (es)
FR (1) FR2953521B1 (es)
GE (1) GEP20156227B (es)
IN (1) IN2012DN04966A (es)
MA (1) MA33882B1 (es)
MX (1) MX2012006578A (es)
NI (1) NI201200099A (es)
PE (1) PE20121475A1 (es)
PH (1) PH12012501053A1 (es)
SA (1) SA110320011B1 (es)
SG (1) SG181082A1 (es)
TN (1) TN2012000267A1 (es)
TW (1) TW201200499A (es)
UA (1) UA102950C2 (es)
UY (1) UY33072A (es)
WO (1) WO2011070253A1 (es)
ZA (1) ZA201203943B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015032966A1 (en) * 2013-09-09 2015-03-12 Sanofi An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
ES2342979T3 (es) * 2005-11-30 2010-07-20 F. Hoffmann-La Roche Ag Derivados de indol-2-carboxamida sustituidos en 5.

Also Published As

Publication number Publication date
IN2012DN04966A (es) 2015-09-25
AU2010329762A1 (en) 2012-06-21
AP2012006352A0 (en) 2012-08-31
EA201200849A1 (ru) 2013-01-30
PH12012501053A1 (en) 2013-02-04
EP2509947A1 (fr) 2012-10-17
CU20120091A7 (es) 2012-07-31
SA110320011B1 (ar) 2013-10-01
ZA201203943B (en) 2013-08-28
CA2782469A1 (fr) 2011-06-16
SG181082A1 (en) 2012-07-30
NI201200099A (es) 2012-11-09
TW201200499A (en) 2012-01-01
UY33072A (es) 2011-05-31
AU2010329762B2 (en) 2013-10-03
BR112012013666A2 (pt) 2016-04-19
US20120283245A1 (en) 2012-11-08
KR20120102763A (ko) 2012-09-18
FR2953521A1 (fr) 2011-06-10
WO2011070253A1 (fr) 2011-06-16
CA2782469C (fr) 2014-04-08
GEP20156227B (en) 2015-01-26
UA102950C2 (ru) 2013-08-27
WO2011070253A8 (fr) 2012-08-02
CL2012001479A1 (es) 2013-02-08
TN2012000267A1 (fr) 2013-12-12
CR20120286A (es) 2012-08-20
FR2953521B1 (fr) 2011-11-18
AR079265A1 (es) 2012-01-04
JP2013513589A (ja) 2013-04-22
ECSP12011950A (es) 2012-07-31
CO6541535A2 (es) 2012-10-16
MA33882B1 (fr) 2013-01-02
MX2012006578A (es) 2012-06-25
CN102652127A (zh) 2012-08-29

Similar Documents

Publication Publication Date Title
HN2012001744A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
ECSP11011427A (es) Piperidinas sustituidas como antagonistas de ccr3.
EA201391158A8 (ru) Диаминиевые соли фенотиазина и их применение
CO2020011852A2 (es) Inhibidores de canales receptores de potencial transitorio de oxadiazol
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201490287A1 (ru) Новые замещенные производные индола в качестве модуляторов гамма-секретазы
EA201390934A1 (ru) Композиции и способы модулирования fxr
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
UY34964A (es) Derivados de cromano como inhibidores del receptor transitorio potencial de la melastatina 8 (trpm8)
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
ECSP11010804A (es) Compuestos orgánicos
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
UY29457A1 (es) Compuestos novedosos de derivados de aminosulfonilo
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
PE20081703A1 (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
EA201391124A1 (ru) Новые бензодиоксолпиперазиновые соединения
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.
ECSP11011415A (es) Piperidinas sustituidas como antagonistas de ccr3.
PE20100139A1 (es) Nuevas n-(2-amino-fenil)-acrilamidas
CO6580197A1 (es) Procedimiento de sisntesis y forma cristalina del hidrocloruro de 4-{3-[cis-hewahidrociclopenta[c]pirrol} -2(1h)-il]propoxi}benzamida así como las composiciones farmaceuticas que la contienen
PE20121475A1 (es) Nuevos derivados de azabiciclo[3.1.0]hex-2-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FD Application declared void or lapsed